Associate Professor Ki-Bum Lee has developed patent-pending technology that may overcome one of the critical barriers to harnessing the full therapeutic potential of stem cells.
One of the major challenges facing researchers interested in regenerating cells and growing new tissue to treat debilitating injuries and diseases such as Parkinson’s disease, heart disease, and spinal cord trauma, is creating an easy, effective, and non-toxic methodology to control differentiation into specific cell lineages. Lee and colleagues at Rutgers and Kyoto University in Japan have invented a platform they call NanoScript, an important breakthrough for researchers in the area of gene expression. Gene expression is the way information encoded in a gene is used to direct the assembly of a protein molecule, which is integral to the process of tissue development through stem cell therapeutics.
Stem cells hold great promise for a wide range of medical therapeutics as they have the ability to grow tissue throughout the body. In many tissues, stem cells have an almost limitless ability to divide and replenish other cells, serving as an internal repair system.
Transcription factor (TF) proteins are master regulators of gene expression. TF proteins play a pivotal role in regulating stem cell differentiation. Although some have tried to make synthetic molecules that perform the functions of natural transcription factors, NanoScript is the first nanomaterial TF protein that can interact with endogenous DNA. ACS Nano, a publication of the American Chemical Society (ACS), has published Lee’s research on NanoScript. The research is supported by a grant from the National Institutes of Health (NIH).
“Our motivation was to develop a highly robust, efficient nanoparticle-based platform that can regulate gene expression and eventually stem cell differentiation,” said Lee, who leads a Rutgers research group primarily focused on developing and integrating nanotechnology with chemical biology to modulate signaling pathways in cancer and stem cells. “Because NanoScript is a functional replica of TF proteins and a tunable gene-regulating platform, it has great potential to do exactly that. The field of stem cell biology now has another platform to regulate differentiation while the field of nanotechnology has demonstrated for the first time that we can regulate gene expression at the transcriptional level.”
NanoScript was constructed by tethering functional peptides and small molecules called synthetic transcription factors, which mimic the individual TF domains, onto gold nanoparticles.
“NanoScript localizes within the nucleus and initiates transcription of a reporter plasmid by up to 30-fold,” said Sahishnu Patel, Rutgers Chemistry graduate student and co-author of the ACS Nano publication. “NanoScript can effectively transcribe targeted genes on endogenous DNA in a nonviral manner.”
The Latest on: Stem Cell Therapeutics
via Google News
The Latest on: Stem Cell Therapeutics
- California stem-cell advocates plead for mail-in signatures to put measure on balloton April 7, 2020 at 3:23 pm
Supporters of a proposed $5.5 billion bond measure that would keep California’s stem-cell research institute in business are asking thousands of people to mail in their signatures in hopes of ...
- Cell and Gene Therapy Sector Needs to Automateon April 7, 2020 at 12:00 pm
Cell and gene therapy firms are not ready to fully embrace artificial intelligence (AI ... that are generating novel methods to add or remove genetic material to cells, therefore enhancing their ...
- Pluristem jumps 55% premarket on positive effect of PLX cells in COVID-19on April 7, 2020 at 10:14 am
Thinly traded nano cap (NASDAQ:PSTI) spikes 55% premarket on increased volume in reaction to preliminary data on the use of its PLX cells in severely ill COVID-19 patients in Is ...
- New CAR T-Cell Therapy Finds Niche in R/R Mantle Cell Lymphomaon April 7, 2020 at 8:39 am
"All the patients underwent leukapheresis to obtain cells for KTE-X19 manufacturing," the authors note ... Further, cytokine release syndrome (CRS), a well-recognized AE of all CAR T-cell therapy, ...
- CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)on April 7, 2020 at 6:03 am
NEW YORK and AUSTIN, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics (“Cytovia”), an emerging biopharmaceutical company ...
- Coronavirus Update: Cell Therapy Reportedly Appears Promising To Beat COVID-19on April 7, 2020 at 12:45 am
Cell therapy using immune cells from young and healthy volunteers developed by the creators of 'Dolly the sheep' and another experimental cell therapy appeared promising in treating the deadly ...
- Stem Cell Therapy Market Brief Analysis by Top Key Players : Astellas Pharma Inc, Celyad, DiscGenics, Gamida Cell, Mesoblast Ltdon April 6, 2020 at 7:12 pm
As per Global Market Insights Inc. estimates, stem cell therapy market size is projected to surpass $15 billion by 2025. Ocean View, DE -- (SBWIRE) -- 04/06/2020 -- How will prevalence of chronic ...
- Next-generation stem cells — ushering in a new era of cell-based therapieson April 6, 2020 at 2:10 am
Primary stem cells have long been used therapeutically for applications such as bone marrow transplantation. This Review discusses how cell-engineering approaches are enabling the development of ...
- Celularity's Dr. Robert Hariri on testing stem cell therapy for coronavirus patientson April 3, 2020 at 2:59 pm
Robert Hariri, founder, chairman and CEO of Celularity, join "Squawk Alley" to discuss the testing of new stem cell treatments for coronavirus patients.
- Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patientson April 2, 2020 at 6:10 am
The treatment, which has been promoted by President Trump’s personal lawyer, Rudy Giuliani, will begin early-stage clinical trials. By Katie Thomas An experimental stem cell therapy derived from human ...
via Bing News